Latest News

  • Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder Read More
  • Alkermes to Acquire Rodin Therapeutics Read More
  • Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences Read More

Investors

ALKS investor relations
Learn more Learn More

Pipeline

patient focused CNS disorder treatments
See Our Approach See Our Approach

Working at Alkermes

career opportunities at Alkermes
Working at Alkermes Join Our Team